Dihexa
N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Angiotensin-IV / HGF-mimetic research amide from the WSU lineage. The “10 million × BDNF” line is an assay comparison, not a human cognition RCT. Not an Alzheimer or Parkinson drug.
Quick answer
What it is: Angiotensin-IV / HGF-mimetic research amide from the WSU lineage.
Typical research dose: 10-40 mg/day (oral/intranasal)
Research summary, not medical advice.
Use-case scores
- Cognition3/10
Compound card
- Sequence
- N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide
- Class
- Angiotensin-IV / HGF-mimetic research amide (WSU lineage)
- Formula
- C21H33N3O4
- Status
- Not FDA-approved · research use
How it works
Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a synthetic peptide analog of angiotensin IV that acts on hepatocyte growth factor (HGF) receptors. It is reported to be 10^7 (ten million) times more potent than BDNF (Brain-Derived Neurotrophic Factor) at promoting spinogenesis - the formation of new dendritic spines that enable synaptic connections.
Dihexa crosses the blood-brain barrier and promotes synaptogenesis, which may enhance learning, memory, and cognitive function. It was developed at Washington State University as a potential therapeutic for neurodegenerative diseases including Alzheimer's.
Source: PMID: 23123685
Background & History
Dihexa is an angiotensin-IV / HGF-mimetic research amide from the WSU lineage. Assay potency versus BDNF is not a human cognition RCT. Not an Alzheimer or Parkinson drug.
Research Use Cases
- ✓HGF/c-Met research-amide identity
- ✓The “10 million × BDNF” line as an assay comparison, not a clinical multiplier
- ✓Not a stroke, TBI, or dementia protocol
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Standard Protocol | 10 - 40 mg | Daily (oral or intranasal) | Extremely potent. Effects persist >48h. Not used by SC injection. |
Administration
Timeline
Who it is for
Cognitive Enhancement / Nootropic
Low10 million times more potent than BDNF at spinogenesis in vitro. Very limited human data.
Neurodegenerative Disease Research
LowDeveloped for Alzheimer's research. Powerful but data is almost entirely preclinical.
Safety & Considerations
Research peptide with very limited human data. Extremely potent - doses measured in mg/day. Oral or intranasal only. Consult a healthcare provider before use.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- No Western Phase 3 cognition label.
- This site will not treat Alzheimer disease from a peptide page.
- Potency vs BDNF in an assay is not a 10-million-times smarter claim.
Verdict
Dihexa is a research amide from the angiotensin-IV / HGF story. It is not an Alzheimer drug. Oral or SubQ research use is not a Washington State clinical program.
Interactions & Contraindications
Limited human safety file. Start low if used at all. Avoid with active CNS tumors. This site will not treat Alzheimer disease from a peptide page.
Synergies & Common Stacks
Two nootropic SKUs. Complementary marketing is not a recovery RCT.
Appears in goal guides
Goal guides are maps, not clinic protocols. A mention here is not a treatment plan.
Cognitive Enhancement & Nootropic Drive
Identity map for Semax, Selank, Noopept, and related nootropic SKUs. BDNF language is mechanism, not a US cognition or stroke indication.
Cognitive Enhancement Protocol
Neuro 3 Plus bioregulator triad (brain, vessels, liver) plus Semax/Selank, with Dihexa reserved for advanced users.
Frequently Asked Questions
Is Dihexa injectable?▼
How potent is Dihexa vs BDNF?▼
Prescription options: compare licensed telehealth providers
Some peptide therapies are available only by prescription after a consult with a licensed clinician.